Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients
Authors
Keywords
Immunotherapy, PD-L1, PD-1, Lung cancer, Immunohistochemistry, Diagnostic pitfalls
Journal
VIRCHOWS ARCHIV
Volume 468, Issue 5, Pages 511-525
Publisher
Springer Nature
Online
2016-02-25
DOI
10.1007/s00428-016-1910-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PD-L1 Testing in Cancer
- (2016) Aaron R. Hansen et al. JAMA Oncology
- PD-L1 Expression as a Predictive Biomarker
- (2016) Feriyl Bhaijee et al. JAMA Oncology
- Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
- (2016) Joseph McLaughlin et al. JAMA Oncology
- Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy
- (2016) Dickran Kazandjian et al. JAMA Oncology
- European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women?
- (2015) M. Malvezzi et al. ANNALS OF ONCOLOGY
- Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies
- (2015) M. Ilie et al. ANNALS OF ONCOLOGY
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Addressing the unmet need in lung cancer: The potential of immuno-oncology
- (2015) G.V. Scagliotti et al. CANCER TREATMENT REVIEWS
- Immune Checkpoint Modulation for Non-Small Cell Lung Cancer
- (2015) J.-C. Soria et al. CLINICAL CANCER RESEARCH
- Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non-Small Cell Lung Cancer
- (2015) V. K. Anagnostou et al. CLINICAL CANCER RESEARCH
- PD-1/PD-L1 inhibitors
- (2015) Joel Sunshine et al. CURRENT OPINION IN PHARMACOLOGY
- PD-L1 expression in small cell lung cancer
- (2015) Takefumi Komiya et al. EUROPEAN JOURNAL OF CANCER
- PD-L1 expression in small cell neuroendocrine carcinomas
- (2015) Anne M. Schultheis et al. EUROPEAN JOURNAL OF CANCER
- Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC
- (2015) Jan Trøst Jørgensen EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
- (2015) Lieping Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?
- (2015) Keith M. Kerr et al. Journal of Thoracic Oncology
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- PD-L1 Blockade for Cancer Treatment: MEDI4736
- (2015) Ramy Ibrahim et al. SEMINARS IN ONCOLOGY
- Adaptive Immune Resistance: How Cancer Protects from Immune Attack
- (2015) A. Ribas Cancer Discovery
- Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) M. Reck et al. ANNALS OF ONCOLOGY
- Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
- (2014) Z. Gatalica et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- The Future of Cancer Therapy: Selecting Patients Likely to Respond to PD1/L1 Blockade
- (2014) A. Ribas et al. CLINICAL CANCER RESEARCH
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes
- (2014) Ching-Yao Yang et al. EUROPEAN JOURNAL OF CANCER
- Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC
- (2014) Stéphane Champiat et al. Journal of Thoracic Oncology
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- L’accréditation selon la norme ISO 15189 d’un laboratoire de pathologie et de génétique somatique (LPCE, CHU de Nice) : retour d’expérience
- (2013) Kevin Washetine et al. ANNALES DE PATHOLOGIE
- A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells
- (2013) I. B. Barsoum et al. CANCER RESEARCH
- Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
- (2013) M. Sznol et al. CLINICAL CANCER RESEARCH
- ALKin Lung Cancer: Past, Present, and Future
- (2013) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours
- (2013) Jérôme Galon et al. JOURNAL OF PATHOLOGY
- Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
- (2013) Chee Khoon Lee et al. JNCI-Journal of the National Cancer Institute
- Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1)
- (2013) Vamsidhar Velcheti et al. Journal of Thoracic Oncology
- The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
- (2013) Paolo A Ascierto et al. Journal of Translational Medicine
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- Tumor B7-H1 and B7-H3 Expression in Squamous Cell Carcinoma of the Lung
- (2012) Jennifer M. Boland et al. Clinical Lung Cancer
- Pitfalls in Lung Cancer Molecular Pathology: How to Limit them in Routine Practice?
- (2012) M. Ilie et al. CURRENT MEDICINAL CHEMISTRY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Overall survival and PD-L1 expression in metastasized malignant melanoma
- (2010) Jules Gadiot et al. CANCER
- Quantitative Analysis of Tumor in Bronchial Biopsy Specimens
- (2010) Caroline L. Coghlin et al. Journal of Thoracic Oncology
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
- (2008) M. Marzec et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started